论文部分内容阅读
目的 :观察协良行与左旋多巴合用治疗帕金森氏病的疗效及安全性等 ;方法 :选择特发性帕金森氏病 2 6例 ,在原有的治疗基础上加用协良行 ( 0 .5～ 1 .5)mg d ,并分别比较其治疗前后PDRS(简化帕金森氏病分级量表评分 )、改良Hoehn -Yahr分级评分等变化 ;结果 :加用协良行后患者其日常活动能力评分、运动功能评分、“关”状态时数、Hoehn -Yahr分级评分及PDRS总评分均较治疗前显著改善 ,P <0 .0 5;结论 :协良行作为左旋多巴的联用药物 ,可明显改善帕金森氏病患者的临床症状及减少左旋多巴用量 ,且安全可靠
Objective: To observe the curative effect and safety of the combination of Xie Lian Xing and levodopa in the treatment of Parkinson’s disease. Methods: Twenty-six patients with idiopathic Parkinson’s disease were selected. Based on the original treatment, ~ 1.5) mg d before and after treatment, and compared their changes of PDRS (simplified Parkinson’s disease grading scale) and modified Hoehn-Yahr grading before and after treatment.Results: The score of daily activities, Motor function scores, “off” state hours, Hoehn-Yahr grading and total PDRS scores were significantly improved compared with before treatment, P <0. 05; Conclusion: As a synergistic effect of levodopa, Parkinson’s disease in patients with clinical symptoms and reduce levodopa dosage, and safe and reliable